H. Huisman

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

J. Verweij, E. de Vries, J. Gietema, 2007, British Journal of Cancer.

Phase 1 study with BIBW 2992, an irreversible dual tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) in a 2 week on 2 week off schedule.

E. D. de Vries, J. Verweij, M. D. de Jonge, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic results from two phase I dose escalation studies of once daily oral treatment with BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

J. Verweij, J. Marshall, J. Gietema, 2005 .

Population Impact of Girls-Only Human Papillomavirus 16/18 Vaccination in The Netherlands: Cross-Protective and Second-Order Herd Effects

J. Berkhof, I. Molenaar, H. D. de Melker, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors

I. Molenaar, H. D. de Melker, C. Hoebe, 2017, The Journal of infectious diseases.

Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration.

J. Wanders, M. Borner, P. Fumoleau, 2002, European journal of cancer.

The association between viral load and concurrent human papillomavirus infection at the genital and anal sites of young women and the impact of vaccination

I. Molenaar, M. Peeters, C. D. de Haan, 2021, Tumour virus research.